The HOPE TIPS: The HOPE Study Translated into Practices
- Norman Sharpe MD FRACP FACC
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The HOPE TIPS study assessed the practicality and tolerability of ramipril titration to a target dose of 10 mg (as achieved in definitive efficacy studies) in a clinical practice setting. 3881 patients at high cardiovascular risk (HOPE study criteria) were recruited in primary and specialist care settings in 9 countries by 439 investigators. Dose titration of ramipril from 2.5 mg to 10 mg daily took place over 9–12 weeks. The mean age of the patients was 64 years, 60% were male and 79% Asian. The target dosage of 10 mg daily was reached in 73% of patients with 96% of patients achieving 5 mg or 10 mg daily. During the study period uncontrolled hypertension (> 160/90) was recorded in 15% of patients, myocardial infarction or unstable angina 1.6%, heart failure 0.4%, new diabetes 0.6%. Only 9.8% of patients discontinued treatment with 5.9% attributed to treatment side-effects and 4% related to cough. The large majority of patients in a wide range of clinical practice settings with high cardiovascular risk can be treated with ramipril titrated to 10 mg daily with good tolerability.
- Murray CJL, Lopez AD, eds. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston: Harvard School of Public Health, 1996.
- Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937–953. CrossRef
- Third Joint Task Force of the European and other Societies. European guidelines on cardiovascular disease prevention in clinical practice. New Euro J CV Prev and Rehab 2003;10(Suppl 1):S11–S78.
- New Zealand Guidelines Group. The Assessment and Management of Cardiovascular Risk. December 2003.
- Heart Outcomes Prevention Evaluation (HOPE) study investigators. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–153.
- Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary heart disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782–788. CrossRef
- The PEACE Trial Investigators. Angiotensin converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058–2068.
- Antithrombotic Trialists’ Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71–86.
- Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: An overview of the randomised trials. Prog Cardiovasc Dis 1985;27:335–371.
- Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival (4S) Study. Lancet 1994;334:1383–1389.
- Yusuf S, Clinical, public health and research implications of the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 2001;22:103–104. CrossRef
- Sharpe N. Matching the standards of clinical trial evidence with application in practice. Int J Clin Pract 2002;56:772–775.
- Kaplan NM. The CARE study, a postmarketing evaluation of ramipril in 11,100 patients. Clin Ther 1996;18:658–670. CrossRef
- The HOPE TIPS: The HOPE Study Translated into Practices
Cardiovascular Drugs and Therapy
Volume 19, Issue 3 , pp 197-201
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- cardiovascular risk
- Industry Sectors
- Author Affiliations
- 1. University of Auckland, PO Box 17160, Greenlane, Auckland, 1130, New Zealand